Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer.

Oncotarget - 14 Feb 2017

Normanno Nicola, Denis Marc G, Thress Kenneth S, Ratcliffe Marianne, Reck Martin

Abstract excerpt

Cancer treatment is evolving towards therapies targeted at specific molecular abnormalities that drive tumor growth. Consequently, to determine which patients are eligible, accurate assessment of molecular aberrations within tumors is required. Obtaining sufficient tumor tissue for molecular testing can present challenges; therefore, circulating free tumor-derived DNA (ctDNA) found in blood plasma has been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to DNA Mutational Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Practice Guidelines as Topic

Share to Predictive Value of Tests

Share to Reproducibility of Results

Source

Open in PubMed Open full text

Identifiers

PMID: 27980215
DOI: 10.18632/oncotarget.13915
PMCID: PMC5355360

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer.PMID 27980215Read ↗

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung CancerSemantic proximity Read ↗

Circulating Tumour DNA in EGFR-Mutant Non-Small-Cell Lung CancerSemantic proximity Read ↗

The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer.Semantic proximity Read ↗

Role of circulating-tumor DNA analysis in non-small cell lung cancer.Semantic proximity Read ↗

Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectivesSemantic proximity Read ↗

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer.Semantic proximity Read ↗

Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction.Semantic proximity Read ↗

Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs.Semantic proximity Read ↗

Clinical Utility of ctDNA Analysis in Lung Cancer—A ReviewSemantic proximity Read ↗

The promises and perils of circulating tumor DNA for monitoring immunotherapy response in non-small cell lung cancerSemantic proximity Read ↗

Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient ManagementSemantic proximity Read ↗

ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.